Effect of Angiogenesis Induced by Consecutive Intramuscular Injections of Vascular Endothelial Growth Factor in a Hindlimb Ischemic Mouse Model

Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 3, 2014, Pages 225-229

  Lee, Tai Kyoung ^a   Hwang, Hyosook ^a   Na, Kyung Sook ^a   Kwon, JeongIl ^a   Jeong, Hwan Seok ^a   Oh, Philsun ^a   Kim, Hee Kwon ^a   Lim, Seok Tae ^a   Sohn, Myung Hee ^a   Jeong, Hwan Jeong ^a   Lee, Chang Moon ^b  

^a Chonbuk National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Angiogenesis; Consecutive injection; Gamma imaging; Hindlimb ischemia; Perfusion; VEGF

Indexed keywords

PERTECHNETIC ACID TC 99M; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD FLOW; CONTROLLED STUDY; FEMALE; HINDLIMB; IMMUNOHISTOCHEMISTRY; ISCHEMIA; ISCHEMIC INJURY; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84906772157     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-014-0273-5     Document Type: Article

References (12)

1. Al SH. Therapeutic angiogenesis in cardiovascular disease. J Cardiothorac Surg. 2007;2: 49.
2. Ahn SH, Min SI, Kin SY, Min SK, Yang HK, Kim SJ, et al. Effect of nanoparticle with VEGF in mouse ischemic hindlimb model. J Korean Surg Soc. 2010;79: 294-9.
3. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg. 2003;38: 198-203.
4. Hoeben A, Landuyt B, Highley MS, Wildiers H, van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56: 549-80.
5. Biscetti F, Straface G, Arena V, Stigliano E, Pecorini G, Rizzo P. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulation. Cardiovasc Diabetol. 2009;8: 49.
6. Zhu WH, Maclntyre A, Nicosia RF. Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model. Am J Pathol. 2002;161(3): 823-30.
7. Yamada K, Ushio Y, Hayakawa T, Kalo A, Yamada N, Mogami H. Quantitative autoradiographic measurements of blood-brain barrier permeability in the rat glioma model. J Neurosurg. 1982;57: 394-8.
8. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011;71(5): 1573-83.
9. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 2007;71(7): 637-45.
10. Jośko J, Gwóźdź B, Jedrzejowska-Szypułka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit. 2000;6(5): 1047-52.
11. Lee YS. Radiopharmaceuticals for molecular imaging. Open Nucl Med J. 2010;2: 178-85.
12. Min JJ. Monitoring gene therapy by radionuclide approaches. Nucl Med Mol Imaging. 2006;40(2): 96-105.